SkylineDx, a Dutch-based innovative biotechnology company specialising in the development and commercialization of genetic tests, has launching its MMprofiler assay. This test enables clinicians to more accurately predict the prognosis of patients with multiple myeloma (bone marrow cancer) than traditional methods.
The MMprofiler measures the activity of 92 genes which are directly or indirectly related to the disease. These measurements are repeated across different studies, always with the same robustness and predictable outcome, thereby creating a test that is more reliable than traditional methods. Based on gene activity, clinicians can then use the test to predict for their patients how the disease will progress.
The new test is also supported by Prof. Dr. Sonneveld of Erasmus Medical Center in Rotterdam, the Netherlands, who recently received the Robert A. Kyle Lifetime Achievement Award for his work on multiple myeloma:
‘"The key to a successful doctor-patient relationship is good communication – it isn’t rocket science. Ask and involve them, be honest and listen very carefully to what they have to say", says Mr Eric Low, chief executive officer of Myeloma UK, a patient advocacy group.
"We want to be able to predict disease progress based on the genetic properties of the malignant cell. While the current methods accommodate this need to some extent, it makes more sense to mark all genes involved in the incidence of multiple myeloma at once. Based on the profile generated, we can then divide patients based on their better or poorer prognosis."
Subscribe to PharmaTutor News Alerts by Email >>
